Specifically, P-NET rediscovered known genes implicated in CRPC, such as AR, PTEN, TP53 and RB1. Moreover, P-NET identified MDM4 as a relevant gene in this clinical context, which was experimentally validated and may inform use of MDM4-selective inhibitors for genomically stratified (TP53-wild-type) patients with metastatic prostate cancer. This evidence concerns the gene TP53 and metastatic prostate carcinoma.